Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
First-in-disease, Phase 2A multi-center, randomized, double-blind, placebo-controlled,
crossover clinical trial to determine the potential efficacy, safety and pharmacokinetics of
ES-481 in adult patients with drug resistant epilepsy. The study will consist of five
periods.Participants will be randomly assigned to daily dosing of ES-481 or placebo based on
the randomization scheme. The proposed starting oral dose of study medication in each
treatment period is 25 mg qd in the morning and the proposed maximum dose is 75 mg bid.